Chemotherapy Outcomes in Advanced Breast Cancer
Author Information
Author(s): W.M. Gregory, P. Smith, M.A. Richards, C.J. Twelves, R.K. Knight, R.D. Rubens
Primary Institution: Imperial Cancer Research Fund, Clinical Oncology Unit, Guy's Hospital
Hypothesis
What factors influence the response to chemotherapy in patients with advanced breast cancer?
Conclusion
Chemotherapy for advanced breast cancer is often palliative, with a response rate of 34% for first-line treatment and lower rates for subsequent lines.
Supporting Evidence
- The response rate following first line treatment was 34%.
- Median duration of response was 7.8 months.
- Median survival for all patients from the start of chemotherapy was 7.9 months.
- Response rates for second line chemotherapy were significantly lower at 16%.
- Factors predicting for response included the use of anthracycline-based regimens.
Takeaway
This study looked at how well chemotherapy works for women with advanced breast cancer and found that only about one in three patients respond well to the first treatment.
Methodology
Data from 758 patients who received chemotherapy for advanced breast cancer were analyzed to evaluate response rates and factors influencing outcomes.
Potential Biases
The non-randomized nature of the study may introduce selection bias.
Limitations
The study did not include performance status in the analysis, which could affect the results.
Participant Demographics
Patients ranged in age from 19 to 81 years, with various tumor characteristics and treatment histories.
Statistical Information
P-Value
<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website